Pharmaceutical giant Merck has decided to acquire the British company Verona Pharma for about 10 billion dollars, paying 107 dollars per share, a 23% premium. The strategic move comes amid Merck's desire to diversify its revenue streams, given that the patent for its Keytruda oncology treatment will expire in 2028. This is a continuation of Merck's efforts to expand its portfolio, given previous acquisitions including Prometheus Biosciences.
Sources
Latest News
09:20
The Football Association of Wales is withdrawing its support for Gianni Infantino in leading FIFA.
09:10
Romania authorizes nearly 900 bear sacrifices in 2026 and 2027, under the attention of the Italian press
09:06
Traffic restrictions in the counties of Arad, Bihor, and Satu Mare, due to the red heatwave alert.
08:46
Emergency meeting at the Ministry of Energy. Major industrial consumers convened to discuss voluntary reduction of electricity consumption.
08:27
EXCLUSIVE | August 3, 2026. Trends in online searches / last 24 hours
See more news